Coherus BioSciences Inc Market Cap ($131.36 Million)
Market Cap & Net Worth: Coherus BioSciences Inc (CHRS)
Coherus BioSciences Inc market cap. Coherus BioSciences Inc (NASDAQ:CHRS) has a market capitalization of $131.36 Million ($131.36 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #17993 globally and #4232 in its home market, demonstrating a -20.54% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Coherus BioSciences Inc's stock price $0.85 by its total outstanding shares 154500966 (154.50 Million). Also see Coherus BioSciences Inc cash conversion from operations for how efficiently the company converts equity into cash flow.
Coherus BioSciences Inc Market Cap History (2015–2026)
Coherus BioSciences Inc market cap history from 2015 to 2026. Data shows change from $3.55 Billion to $131.36 Million (-26.01% CAGR). Check latest Coherus BioSciences Inc stock price today for real-time trading data and today's change.
Index Memberships
Coherus BioSciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.01% | #491 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #1739 of 3165 |
Weight: Coherus BioSciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Coherus BioSciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Coherus BioSciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Coherus BioSciences Inc (CHRS) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
5.20x
Coherus BioSciences Inc's market cap is 5.20 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $4.35 Billion | $190.11 Million | -$127.34 Million | 22.88x | N/A |
| 2017 | $1.36 Billion | $1.56 Million | -$238.17 Million | 873.78x | N/A |
| 2018 | $1.40 Billion | $1.56 Million | -$209.34 Million | 898.61x | N/A |
| 2019 | $2.78 Billion | $356.07 Million | $89.83 Million | 7.81x | 30.97x |
| 2020 | $2.69 Billion | $475.82 Million | $132.24 Million | 5.64x | 20.31x |
| 2021 | $2.47 Billion | $326.55 Million | -$287.10 Million | 7.55x | N/A |
| 2022 | $1.22 Billion | $211.04 Million | -$291.75 Million | 5.80x | N/A |
| 2023 | $514.49 Million | $257.24 Million | -$237.89 Million | 2.00x | N/A |
| 2024 | $213.21 Million | $266.96 Million | $28.51 Million | 0.80x | 7.48x |
| 2025 | $219.39 Million | $42.17 Million | -$170.29 Million | 5.20x | N/A |
Competitor Companies of CHRS by Market Capitalization
Companies near Coherus BioSciences Inc in the global market cap rankings as of November 5, 2026. Also see CHRS total assets for a full breakdown of the balance sheet.
Key companies related to Coherus BioSciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Coherus BioSciences Inc (2015–2026)
Market capitalization of Coherus BioSciences Inc from 2015 to today. Between 2015 and today, Coherus BioSciences Inc's market cap moved from $3.55 Billion to $ 131.36 Million, with a yearly change of -26.01%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $131.36 Million | -40.13% |
| 2025 | $219.39 Million | +2.90% |
| 2024 | $213.21 Million | -58.56% |
| 2023 | $514.49 Million | -57.95% |
| 2022 | $1.22 Billion | -50.38% |
| 2021 | $2.47 Billion | -8.17% |
| 2020 | $2.69 Billion | -3.47% |
| 2019 | $2.78 Billion | +98.95% |
| 2018 | $1.40 Billion | +2.84% |
| 2017 | $1.36 Billion | -68.74% |
| 2016 | $4.35 Billion | +22.60% |
| 2015 | $3.55 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Coherus BioSciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $131.36 Million USD |
| MoneyControl | $131.36 Million USD |
| MarketWatch | $131.36 Million USD |
| marketcap.company | $131.36 Million USD |
| Reuters | $131.36 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Coherus BioSciences Inc
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin… Read more